Sanofi (SNY) Income from Continuing Operations (2009 - 2026)
Sanofi (SNY) posted Income from Continuing Operations of $438.21 million for the quarter ended Jun 30, 2026, down 68.7% from $1.4 billion a year earlier and down 76.5% from the prior quarter.
Sanofi (SNY) Income from Continuing Operations (2009 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Income from Continuing Operations at Sanofi was $2.33 billion, down 66.8% year-over-year; for the year ended Dec 31, 2025, it was $5.62 billion, down 6.5% from the prior year.
- Annual Income from Continuing Operations shows a five-year compound annual growth rate of -16.8% (years ended Dec 2020 to Dec 2025).
- In prior years, Sanofi's Income from Continuing Operations was $6.01 billion in the year ended Dec 31, 2024 (+9.0%), $5.51 billion in the year ended Dec 31, 2023 (-35.3%), $8.52 billion in the year ended Dec 31, 2022 (+14.6%) and $7.43 billion in the year ended Dec 31, 2021 (-47.2%).
- Quarterly Income from Continuing Operations has run from a low of -$6.73 billion in the quarter ended Dec 31, 2025 to a high of $10.14 billion in the quarter ended Dec 31, 2023 over five years.
- On a year-over-year basis, Income from Continuing Operations increased in four of the last seven quarters, with growth averaging 2.5%.
- The strongest year-over-year quarter for Income from Continuing Operations in the past five years was the quarter ended Dec 31, 2022, with growth of 279.2%; the weakest was the quarter ended Dec 31, 2024, with a decline of 92.7%.
- According to Business Quant data, Income from Continuing Operations for the three prior quarters was $1.87 billion (quarter ended Mar 31, 2026), -$6.73 billion (quarter ended Dec 31, 2025) and $6.76 billion (quarter ended Sep 30, 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,144.36 Bn | 1,112.95 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 635.36 Bn | 555.22 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 502.79 Bn | 475.90 Bn | 12.70 Bn | 3.62 Bn |
| 4 | Merck | 356.08 Bn | 310.46 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 300.87 Bn | 264.86 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 264.31 Bn | 237.99 Bn | 12.86 Bn | 2.51 Bn |
| 7 | Amgen | 239.07 Bn | 194.47 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 194.50 Bn | 168.70 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 171.00 Bn | 117.64 Bn | 10.94 Bn | -246.00 Mn |
| 10 | Sanofi | 50.63 Bn | 17.15 Bn | 10.79 Bn | 438.21 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 438.21 Mn |
| Mar 31, 2026 | 1.87 Bn |
| Dec 31, 2025 | -4.38 Bn |
| Sep 30, 2025 | 6.76 Bn |
| Jun 30, 2025 | 1.40 Bn |
| Mar 31, 2025 | 1.81 Bn |
| Dec 31, 2024 | 736.26 Mn |
| Sep 30, 2024 | 3.08 Bn |
| Jun 30, 2024 | 1.15 Bn |
| Mar 31, 2024 | 1.07 Bn |
| Dec 31, 2023 | 2.04 Bn |
| Sep 30, 2023 | 4.61 Bn |
| Jun 30, 2023 | 279.85 Mn |
| Mar 31, 2023 | 3.49 Bn |
| Dec 31, 2022 | 5.39 Bn |
| Sep 30, 2022 | 3.51 Bn |
| Jun 30, 2022 | 375.60 Mn |
| Mar 31, 2022 | 3.17 Bn |
| Dec 31, 2021 | 289.88 Mn |
| Sep 30, 2021 | 4.40 Bn |
Sanofi Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=SNY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "SNY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=SNY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();